Are countries using global fund support to implement HIV drug resistance surveillance? A review of funded HIV grants

Clin Infect Dis. 2012 May:54 Suppl 4:S250-3. doi: 10.1093/cid/cir1013.


The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) is the largest funder of human immunodeficiency virus (HIV) prevention and treatment programs worldwide. Since 2002, the Global Fund has encouraged grant recipients to implement drug resistance surveillance (DRS) as part of treatment programs. We reviewed documentation of 147 grants funded in 2004-2008 (funding rounds 4-8) to assess grantees' use of funds to support HIV DRS. Overall, 94 grants (64%) described HIV DRS as part of the national treatment program. However, only 32 grants (22%) specifically documented DRS as a grant-funded activity. This review provides baseline information suggesting limited use by countries of Global Fund financing to support HIV DRS. Additional assessment is required to evaluate barriers to using Global Fund grants to support DRS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Retroviral Agents / economics
  • Anti-Retroviral Agents / therapeutic use
  • Drug Resistance, Viral
  • Financing, Organized / statistics & numerical data*
  • Global Health / economics*
  • HIV Infections / drug therapy*
  • HIV Infections / economics
  • HIV Infections / prevention & control
  • Health Surveys
  • Humans
  • World Health Organization


  • Anti-Retroviral Agents